Overview
The purpose of this study is to assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma.
Description
Eligible subjects will be randomized (1:1) to receive investigational product (ABP 206 or nivolumab).
All subjects will be treated until disease progression, unacceptable toxicity, or subject withdrawal of consent for a maximum of 24 months of treatment.
The total duration of study participation for each subject will be approximately 26 months.
Eligibility
Key Inclusion Criteria:
- At least 18 years of age.
- Histologically confirmed unresectable or metastatic melanoma.
- Subject has no prior systemic treatment for advanced disease.
- Subject must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST version 1.1).
- Tumor tissue from site of unresectable or metastatic melanoma must be available for biomarker analyses in order to be randomized.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.
Key Exclusion Criteria:
- Subject has had any prior systemic anti-cancer therapy for the treatment of advanced melanoma.
- Known hypersensitivity to monoclonal antibodies or to any of the excipients of the study drug.
- Subject has active central nervous system (CNS) metastases not previously treated.
- Ocular melanoma.
- Subject has active or known immune-mediated disorders.
- Subject has had prior treatment with PD-1/PD-L1 and cytotoxic T lymphocyte- associated protein 4 inhibitors, or other antibodies targeting immune checkpoint pathways.
- Subject has medical conditions requiring systemic immunosuppression with either corticosteroids or other immunosuppressive medications within 14 days of the first dose of investigational product.
Other protocol-defined inclusion/exclusion criteria apply.